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Identity 
Other names: MDC9; Meltrin-gamma; MLTNG; 
MCMP; KIAA0021 
HGNC (Hugo): ADAM9  
Location: 8p11.23 
Local order: TACC1 - PLEKHA2 - HTRA4 - TM2D2 
- ADAM9 - ADAM32 - ADAM5p - ADAM3A - 
ADAM18 - ADAM2; TACC1; 8P11; Transforming, 
acidic coiled-coil containing protein 1; PLEKHA2; 
8P11.23; Pleckstrin homology domain containing, 
family A member 2; HTRA4; 8P11.23; HtrA serine 
peptidase 4; TM2D2; 8P11.23; TM2 domain containing 
2; ADAM9; 8P11.23; a disintegrin and 
metalloproteinase domain 9; ADAM32; 8p11.23; 
ADAM metalloproteinase domain 32; ADAM5P; 
8p11.23; ADAM metallopeptidase domain 5 
pseudogene; ADAM3A; 8p11.23; ADAM 
metallopeptidase domain 3A (Cyritestin 1); ADAM18; 
8p11.22; ADAM metallopeptidase domain 18; 
ADAM2; 8p11.22; ADAM metallopeptidase domain 2. 
Note 
The ADAM9 gene, a member of the ADAM super-
family has metalloprotease, integrin binding and cell
adhesion capacities. It shown the metallo-protease 
domain cleaves insulin beta-chain, TNF-alpha, gelatin, 
beta-casein, fibronectin, as well as shedding of EGF, 
HB-EGF and FGFR2IIIB. The integrin domain 
mediates cellular adhesion through alpha6beta1 and 
alphavbeta5 integrins. The cytoplasmic tail of ADAM9 
has been reported to interact with endophilin 1 
(SH3GL2), SH3PX1 and  
mitotic arrest deficient 2beta. ADAM9 has implicated 
mediated by stress, such as oxidation during 
inflammation and cancer progression. 
DNA/RNA 
Note 
The ADAM9 gene transcript 2 isoforms of mRNA with 
altered splicing results the lost of exon 18 in the second 
isoform of ADAM9 mRNA and early stop codon. 
Description 
ADAM9 gene extends 108,276 base pairs with 22 
exons which gives rise to 2 different ADAM9 trans-
cripts with differential splicing. The mRNA of 
ADAM9 isoform 1 is 4111 base pair and isoform 2 is 
4005. ADAM9 isoform 2 lacks exon 18 of iso-form 1 
in the coding region, which results in a frameshift and 
an early stop codon. The isoform 2 lacks the c-terminal 
transmembrane and cyto-plasmic domains and is a 
secreted form. 
Transcription 
Isoform 1 mRNA of ADAM9 (NM_003816) has a size 
of 4111 bp, isoform 2 mRNA (NM_001005845) has a 
size of 4005 bp. ADAM9 mRNA is equally expressed 
in many tissue. Among cancer progression, ADAM9 
mRNA is relatively highly expressed in prostate cancer 
and breast cancer. However, little is known of 
differential expression between different isoform of 
ADAM9. 
Pseudogene 
No pseudogene has reported for ADAM9. 
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ADAM9 gene is located on chromosome 8p11.23 spread out on 108,276 deoxynucleotides contained 22 exons. The coding sequence of 
ADAM9 is 2460 nucleotides. Two isoforms reported, isoform 1 of ADAM9 carried full-length membrane bond ADAM9 and isoform 2 
carried soluble form of ADAM9 (sADAM9). The sADAM9 is due to alternative splicing in which lost of exon 18 and results in early stop 




Two different isoform of ADAM9 was reported, the 
full length and soluble form of ADAM9. Recent report 
suggests promoter polymorphisms regulated ADAM9 
transcription that plays a protective role against 
Alzheimer's disease. 
Description 
The predicted molecular mass of ADAM9 is about 84 
KDa. ADAM9 contained coding sequence of 2460 
nucleotides which encoding amino acid of 819 
residues. The full length of active ADAM9 contained 
several functional regions including metalloproteinase, 
disintegrin, cystein rich, EGF-like, transmembrane and 
cytoplasmic domains. The pro-domain of ADAM9 was 
removed by furin-type convertase during ADAM9 
translocated onto membrane and become active form. 
Recent reports indicated soluble form of ADAM9 
cloned from human cDNA library that showed 
increased of cancer invasion in malignant progression. 
Expression 
ADAM9 is ubiquitously expressed. SAGE analyses of 
ADAM9 expression demonstrated that ADAM9 is 
expressed in the bone marrow, lymph node, brain, 
retina, heart, skin, muscle, lung, prostate, breast and 
placenta. Increased expression of ADAM9 was 
reported in several cancers, including gastric, breast, 
prostate, colon, and pancreatic cancers. Splicing  
alteration and lost of exon 18 of ADAM9 causes lostf 
transmembrane domain and early stop in soluble form 
of ADAM9. 
Localisation 
Full length has N-terminal signal peptide and a single 
hydrophobic region predicted to be transmembrane 
domain. Hence, the full length of ADAM9 is localized 
to the plasma membrane. Soluble ADAM9 lack the 
transmembrane domain and cytoplasmic domain and to 
be released out of cell. 
Function 
1. Ectodomain shedding: Metalloproteinase domain of 
ADAM9 is zinc dependent. Metallo-proteinase has 
been showed to involve ectodomain shedding (see tabl
below). One such protein is the heparin-binding EGF-
like growth factor (HB-EGF) and amyloid precursor 
protein (APP). 
2. Matrix Degradation: purified metalloproteinase 
domain of ADAM9 showed the ability to digest 
fibronectin, gelatin and beta-casein. Secreted form f 
ADAM9 showed the ability to digest laminin and 
promote cancer invasion. 
3. Cell contact: ADAM9 specifically bind to integrin 
alpha6beta1, a laminin receptor, via disintegrin region of 
ADAM9 through non-RGD mechanism. ADAM9 also 
have been implicated in binding of avbeta5 in divalent 
cation dependent condition, suggests ADAM9 can 
function as adhesion molecule for cell-cell and cell-
martrix interaction. Secreted form of ADAM9 binds 
directly to alpha6beta4 and alpha2beta1 integrin and  
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Two isoforms of ADAM9 with their specific function. Soluble form of ADAM9 has function to active APP either on the same cell or 
neighbor cell. 
 
ability to cleave laminin and promote cancer 
progression. 
4. Cysteine-Rich domain: The ADAM Cysteine-rich 
domain is not found in other organisms, such as virus, 
archaeal, bacterial or plant. The function of cysteine-
rich domain might involved in complement the binding 
ability of disintegrin-mediated interactions. 
 
TABLE: Substrate and Peptide Sequence Cleaved. 
Substrate 
Peptide sequence cleaved  















The table below gives homology between the human 
ADAM9 and others organisms. 
Mutations 
Note 
Single nucleotide polymorphosim analyses of 
chromosome 8 demonstrated about 356 SNP in the 
chromosome 8p11.23. Most of them are located in 
intron of ADAM9. No mutation was reported in 
ADAM9 coding sequence. Recent evidence sug-gests 
promoter polymorphisms that may upregulate ADAM9 






















ADAM9 gene promoter region contained 4 polymorphisms: -542C/T, -600A/C, -963A/G and -1314T/C. 1314C showed higher ADAM9 





ADAM9 has been implicated in prostate cancer 
progression and the production of reactive oxygen 
species. Large cohort of clinic evaluation demonst-
rated ADAM9 is upregulated in prostate cancer in both 
mRNA and protein level. ADAM9 protein expression 
can be upregulated by androgen in AR-positive but not 
in AR-negative prostate cancer cells that is through 
downstream ROS as mediator to induce ADAM9 
expression. ADAM9 protein expression is associated 




Pancreatic ductal adenocarcinomas showing increased 
of ADAM9 expression in microarray analyses and 
clinic evaluation that correlated with poor tumor 
differentiation and shorter overall survival rate. 
Breast cancer 
Note 
ADAM9 expression is 24% positive in normal breast 
tissue and 66% positive in breast carcinomas. Western 
blot studies demonstrated multiform of ADAM9 were 
expressed in breast carcinoma. In addition, recent study 




The increased of ADAM9 expression in lung cancer 
enhanced cell adhesion and invasion of non-small cell 
lung cancer through change adhesion properties and 
sensitivity to growth factors, and increase its capacity 
of brain metastasis. 
Renal cell carcinoma 
Note 
ADAM9 was implicated increased expression in renal 
cell carcinoma and associated with tumor progression. 
It also showed higher of ADAM9 expression is 
associated with shorten patient survival rate. 
Alzheimer's disease 
Note 
The amyloid precursor protein (APP) of Alzheimer's 
disease is a transmembrane protein processed via either
the non-amyloidogenic or amyloidogenic pathways. In 
the non-amyloidogenic pathway, alpha-secretase 
cleaves APP within the Abeta peptide region releasing 
a large soluble fragment sAPPalpha that has 
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neuroprotective properties. In the amyloidogenic 
pathway, beta-secretase and gamma-secretase 
sequentially cleave APP to generate the intact Abeta 
peptide, which is neurotoxic.  
In ADAM9 expression analyses showed increase in 
production of sAPPalpha upon phorbol ester treatmen 
of cell that co-express of ADAM9 and APP. ADAM9 
did not cleave at the Lys16-Leu17 bone but at the 
His14-Gln15 bone in the Abeta domain of APP cleave 
site. Hence, ADAM9 might play role in protective 
against sporadic Alzheimer's disease. 
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